Medical Devices

U.S. FDA grants fast track designation for emphysema therapy

Published in Biotech Business Week, August 22nd, 2005

Aeris Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for the company's program to develop its Bronchoscopic Lung Volume Reduction (BLVR) system as a non-surgical treatment alternative for selected patients with advanced heterogeneous emphysema.

BLVR is intended to reduce lung volume by delivering proprietary pharmaceutical solutions that form a biodegradable gel to treatment sites within the lung through a standard bronchoscopic procedure. Aeris believes that BLVR has the potential to provide clinical benefits similar to those of lung volume reduction surgery while avoiding the extended recovery period...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-08-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry